Long-Acting Versus Standard Non-Ergot Dopamine Agonists in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.

CONCLUSIONS: Our meta-analysis showed long-acting NEDAs were noninferior to standard NEDAs in efficacy, tolerability, and safety in the treatment of PD.
PMID: 24588909 [PubMed - as supplied by publisher]

Source: CNS Neuroscience and Therapeutics - March 3, 2014 Category: Neuroscience Authors: Zhou CQ, Lou JH, Zhang YP, Zhong L, Chen YL, Lu FJ, Peng GG Tags: CNS Neurosci Ther Source Type: research